PSTV_OUT_1 [2025-03-20 09:53:20 -0400] 2224 Bytes | 638 tokens | Cum: 638 tkns (7.98% of 8k)
==========================================================================

Booyah, my friends! It's already 09:53:19 AM on Thursday March 20, 2025 ET (UTC-0400), and I've got my eyes locked on PLUS THERAPEUTICS (PSTV), pushing up to 0.617 from 0.511. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for PLUS THERAPEUTICS:

C1 - Today 07:30AM - Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate
C2 - Mar-19-25 07:30AM - Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
C3 - Mar-11-25 11:00AM - D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
C4 - Mar-10-25 07:30AM - Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
C5 - Mar-07-25 01:49PM - Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday
C6 - Mar-07-25 01:49PM 07:33AM - FDA ODD given to Plus Therapeutics injectable radiotherapy
C7 - Mar-07-25 01:49PM 07:30AM - Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
C8 - Mar-06-25 07:30AM - Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on PLUS THERAPEUTICS (PSTV)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PSTV_OUT_3 [2025-03-20 09:53:23 -0400] 976 Bytes | 292 tokens | Cum: 932 tkns (11.65% of 8k)
==========================================================================

Showing C1 (chunk 1 of 5): C1:
**Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate**
Date: Today 07:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html

March 20, 2025 07:30 ET| Source:Plus Therapeutics Inc.Plus Therapeutics Inc.

REYOBIQ™ (rhenium Re186obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM)

HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) --Plus Therapeutics, Inc.(Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company’s new

-- More? (MOR) or Next section? (NEX)

PSTV_OUT_5 [2025-03-20 09:53:25 -0400] 977 Bytes | 215 tokens | Cum: 1149 tkns (14.36% of 8k)
==========================================================================

Showing C1 (chunk 2 of 5): proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the marketing application (NDA) is submitted. All communications regarding the USAN-adopted and INN-recommended rhenium Re186obisbemeda generic name will now utilize the proprietary name REYOBIQ™.

"Branding is an important part of preparing for commercialization, and the establishment of the REYOBIQ™ brand will enable investigators, investors, and potential patients to connect with our rhenium-based radiotherapeutic beyond its chemical identity," said Russ Havranek, Plus Therapeutics VP of Corporate Strategy and New Product Planning. "We are looking forward to building familiarity with the new REYOBIQ™ name and logo, as we believe it will foster stronger stakeholder engagement and reinforce the promising progress we are making in developing targeted

-- More? (MOR) or Next section? (NEX)

PSTV_OUT_7 [2025-03-20 09:53:26 -0400] 927 Bytes | 282 tokens | Cum: 1433 tkns (17.91% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T12:09:53Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Aditxt (NASDAQ:ADTX), AEON Biopharma...
A2 - 2025-03-20T12:18:00Z - Why Plus Therapeutics Is Rising In Pre-market?...
A3 - 2025-03-20T12:02:33Z - Why Plus Therapeutics Is Rising In Pre-market?...
A4 - 2025-03-20T11:56:39Z - Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate | Taiwa...
A5 - 2025-03-20T11:37:20Z - Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PSTV_OUT_9 [2025-03-20 09:53:28 -0400] 967 Bytes | 314 tokens | Cum: 1749 tkns (21.86% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's Pre-Market Session - Aditxt (NASDAQ:ADTX), AEON Biopharma (AMEX:AEON)**Date: 2025-03-20Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44414692/12-health-care-stocks-moving-in-thursdays-pre-market-sessionGainers OptiNose OPTN shares moved upwards by 58.3% to $9.5 during Thursday's pre-market session. The market value of their outstanding shares is at $95.5 million. Windtree Therapeutics WINT stock increased by 35.5% to $2.29. The company's market cap stands at $1.7 million. Plus Therapeutics PSTV stock rose 20.99% to $0.62. The company's market cap stands at $3.6 million. MSP Recovery MSPR shares moved upwards by 15.56% to $1.63. The company's market cap stands at $3.4 million. AEON Biopharma AEON shares rose 13.01% to $0.85. Aditxt ADTX stock rose 12.96% to $11.33

-- More? (MOR) or Next section? (NEX)

PSTV_OUT_11 [2025-03-20 09:53:29 -0400] 988 Bytes | 286 tokens | Cum: 2037 tkns (25.46% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-04T19:06:00Z - Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
B2 - 2024-07-02T11:30:00Z - Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
B3 - 2024-06-07T11:30:00Z - Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
B4 - 2024-05-17T21:00:00Z - Plus Therapeutics Announces New Employment Inducement Grants
B5 - 2024-05-15T20:15:00Z - Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
B6 - 2024-05-13T11:30:00Z - Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PSTV_OUT_13 [2025-03-20 09:53:35 -0400] 615 Bytes | 153 tokens | Cum: 2192 tkns (27.40% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/04/3036891/0/en/Plus-Therapeutics-Secures-Private-Placement-of-Approximately-15-Million-in-Gross-Proceeds.htmlPlus Therapeutics, a clinical-stage pharmaceutical company, announced the pricing of a $15.0 million private placement. The funds will be used to advance the company's central nervous system cancer therapies and meet key near-term milestones.

-- More? (MOR) or Next section? (NEX)

PSTV_OUT_15 [2025-03-20 09:53:37 -0400] 1156 Bytes | 289 tokens | Cum: 2581 tkns (32.26% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

S2 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

S3 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

PSTV_OUT_17 [2025-03-20 09:53:38 -0400] 967 Bytes | 220 tokens | Cum: 2803 tkns (35.04% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item1.01 Entry Into a Material Definitive Agreement.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agreement) with accredited investors, including certain existing stockholders of the Company, identified on the signature page thereto (collectively, the Purchasers) for a private placement of securities (the Private Placement) for gross proceeds expected at closing of approximately $15.0 million. The Securities Purchase Agreement, provides for the sale and issuance by the Company of an aggregate of 28,042,140 shares (the Private Placement Shares) of the Companys common stock, par value $0.001 per share (Common Stock), or, at the election of each Purchaser, prefunded warrants to purchase Common Stock (the Prefunded Warrants), exercisable immediately at an exercise price of $0.001 per sh

-- More? (MOR) or Next section? (NEX)

PSTV_OUT_19 [2025-03-20 09:54:00 -0400] 5473 Bytes | 1642 tokens | Cum: 4447 tkns (55.59% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Volume: 16,274,972 | SMA50: -43.99% | Market Cap: 7.10M | Option/Short: No / No | Sales past 5Y: 474.41% | Sales Surprise: -0.70% |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 8.81M | SMA200: -56.71% | Shs Outstand: 5.90M | Short Float: 2.44% | Employees: 20 | EPS Surprise: 34.22% |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 27.56 | Perf Week: -19.64% | Shs Float: 5.75M | Short Ratio: 0.02 | Debt/Eq: - | P/E: - |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| RSI (14): 41.75 | Perf Month: -49.77% | Inst Own: 11.50% | Short Interest: 0.14M | Sales Y/Y TTM: 52.63% | Earnings: Mar 27 AMC |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.25 | Perf Quarter: -48.48% | Insider Own: 2.55% | Beta: 0.97 | ROE: -522.50% | |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| SMA20: -31.10% | Index: - | Insider Trans: 0.00% | Sales Q/Q: 17.42% | ROI: - | |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Sims Andrew John Hugh MacIntyre (Chief Financial Officer) on 2025-02-18
- Stock Option (Right to Buy): 60020 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Petersen Greg (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by HEDRICK MARC H (Chief Executive Officer) on 2025-02-18
- Stock Option (Right to Buy): 400489 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by van Es-Johansson An (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Lenk Robert P (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Clowes Howard (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Hawkins Richard J (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: PLUS THERAPEUTICS, Inc. Common Stock
Market Cap: 3013026.163
Shares Outstanding: 5896333
Sector: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1456000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2874000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.612
Average Volume: 23383810.7
30-Day High: 1.57
30-Day Low: 0.3022

[Detailed Financials: Q3 2024]
- Total Assets: $6,978,000.0
- Total Liabilities: $12,152,000.0
- Total Equity: $-5,174,000.0
- Current Assets: $5,364,000.0
- Current Liabilities: $12,112,000.0

[Income Statement: Q3 2024]
- Revenue: $1,456,000.0
- Net Income: $-2,874,000.0
- Operating Income: $-3,799,000.0
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-3,689,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $11,212,000.0
- Total Liabilities: $18,837,000.0
- Total Equity: $-7,625,000.0
- Current Assets: $9,380,000.0
- Current Liabilities: $18,787,000.0

[Income Statement: Q2 2024]
- Revenue: $1,279,000.0
- Net Income: $-2,940,000.0
- Operating Income: $-3,697,000.0
- Earnings Per Share (EPS): -0.45

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,011,000.0
==== END OF FINANCIAL REPORT ====

PSTV_OUT_21 [2025-03-20 09:54:02 -0400] 561 Bytes | 131 tokens | Cum: 4949 tkns (61.86% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PSTV_IN_23 [2025-03-20 09:54:03 -0400] 126 Bytes | 29 tokens | Cum: 4988 tkns (62.35% of 8k)
==========================================================================

====================================
[2025-03-20 06:54:03] # Analysis Completed
Elapsed Time: 44.39 seconds